ALBANY MOLECULAR RESEARCH, INC. ALBANY, N.Y., Feb. 12, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today reported financial and operating results for the fourth quarter and full year ended December 31, 2014.
"While our OsoBio facility resumed full operations later than anticipated, after we learned in the fall of 2014 that a remediation would be necessary, strong execution led us to finish 2014 with record performances in each of our businesses, as reflected by a greater than 30% increase in quarterly revenue and adjusted earnings," said William S. Marth, AMRI's president and chief executive officer.
"During 2014, we reorganized our discovery business, optimizing our resource mix and laying the ground work for a differentiated discovery platform. We advanced our growth in generics, initiating multiple development programs across all segments of our business, and we completed and integrated two acquisitions and announced a third, expanding our capabilities into very attractive, high demand areas such as controlled substances, sterile manufacturing and product development. Lastly, we created sustainable shareholder value, replacing declining royalties with an expanding, profitable contract business.
"We have much to be proud of in 2014 and are poised for a strong 2015. Despite a significant headwind from the loss of Allegra royalties in 2015, we believe continued strong growth in our base business, the contribution of our acquisitions, together with enhanced operational discipline, will lead to continued, significant growth in revenue and earnings in 2015."
Fourth Quarter 2014 Results
Total revenue for the fourth quarter of 2014 was $86.6 million, an increase of 29% compared to total revenue of $67.1 million reported in the fourth quarter of 2013.
Total contract revenue for the fourth quarter of 2014 was $80.7 million, an increase of 35% compared to contract revenue of $59.7 million reported in the fourth quarter of 2013. Adjusted contract margins were 23% for the fourth quarter of 2014, compared with 21% for the fourth quarter of 2013, driven by the growth of the Drug Product business, increased capacity utilization, and the benefit of cost reduction initiatives and facility optimization. Adjusted contract margins exclude the following items that are included under U.S. GAAP: business interruption costs, purchase accounting depreciation and amortization and business acquisition costs. For a reconciliation of U.S. GAAP contract margins as reported to adjusted contract margins for the 2014 and 2013 reporting periods, please see Table 1 at the end of press release.
Royalty revenue in the fourth quarter of 2014 was $5.9 million, a decrease of 21% from $7.4 million in the fourth quarter of 2013. Royalty revenue for the fourth quarter of 2014 includes $3.4 million in royalties from the Allegra(®) products as well as $2.5 million from the net sales of certain amphetamine salts sold by Actavis.
Net loss under U.S. GAAP was $(1.9) million, or $(0.06) per diluted share, in the fourth quarter of 2014, compared to U.S. GAAP net income of $4.3 million, or $0.13 per diluted share for the fourth quarter of 2013. Net income on an adjusted basis in the fourth quarter of 2014 was $9.2 million, or $0.28 per diluted share, compared to adjusted net income of $6.8 million or $0.21 per diluted share in 2013. Net income on an adjusted basis excludes the following items that are included under U.S. GAAP: business interruption charges, restructuring and impairment charges, convertible debt interest and amortization charges, business acquisition costs, executive transition costs, postretirement benefit plan settlement gains, write-offs of deferred financing costs, non-recurring income tax adjustments, litigation settlements, insurance demutualization gains, losses on disposals of fixed assets related to restructuring activities, ERP implementation costs, and depreciation and amortization of purchase accounting adjustments. For a reconciliation of U.S. GAAP net income (loss) and earnings (loss) per diluted share as reported to adjusted net income and earnings per diluted share for the 2014 and 2013 reporting periods, please see Table 2 at the end of this press release.
Full Year 2014 Results
Total revenue for the year ended December 31, 2014 was a record $276.6 million, an increase of 12% compared to total revenue of $246.6 million for the same period in 2013.
Total contract revenue for the full year 2014 was a record $250.7 million, an increase of 19% compared to contract revenue of $210.0 million for 2013. Adjusted contract margins were 19% for the full year 2014, compared to 18% in 2013.
Royalty revenue for the full year 2014 was $25.9 million, a decrease of 29% from $36.6 million in 2013, in line with expectations. Royalty revenue for the full year 2014 includes $16.3 million in royalties from the Allegra(®) products, as well as $9.6 million from the net sales of certain amphetamine salts sold by Actavis.
Net loss under U.S. GAAP for the full year 2014 was $(3.3) million, or $(0.10) per diluted share, compared to U.S. GAAP net income of $11.8 million, or $0.37 per diluted share for the full year 2013. Net income on an adjusted basis in the full year 2014 was $20.7 million or $0.63 per diluted share, compared to adjusted net income of $21.5 million or $0.68 per diluted share in 2013. Adjusted net income in 2014 includes a $6.4 million decline in royalty income and $0.7 million of income from operations acquired during 2014.
For a reconciliation of U.S. GAAP net income (loss) and earnings (loss) per diluted share as reported to adjusted net income and earnings per diluted share for the 2014 and 2013 reporting periods, please see Table 2 at the end of this press release. Financial results for the three months and year ended December 31, 2013 have been updated from previously reported amounts to reflect prior period income tax adjustments identified during the second quarter of 2014. The Company considers the adjustments to be immaterial to the impacted periods.
Segment Results
Drug Discovery Services (DDS)
Three Months Ended Year Ended
December 31, December 31,
------------ ------------
(Unaudited; $ in thousands) 2014 2013 2014 2013
---- ---- ---- ----
DDS Contract Revenue $19,741 $18,404 $76,737 $77,418
Cost of Contract Revenue 15,482 16,028 62,401 66,604
------ ------ ------ ------
Contract Gross Profit 4,259 2,376 14,336 10,814
Contract Gross Margin 22% 13% 19% 14%
Discovery and Development Services (DDS) contract revenue for the fourth quarter of 2014 increased 7% to $19.7 million, compared to $18.4 million the fourth quarter of 2013, primarily due to an increase in development services revenue. DDS gross margins increased to 22% from 13% in the fourth quarter of 2013, driven by the benefit of cost reduction initiatives and facility optimization.
For the full year 2014, DDS contract revenue decreased to $76.7 million from $77.4 million in 2013. A decline in discovery service revenue was offset by an increase in development service revenue. DDS gross margins increased to 19% in 2014 from 14% in 2013, driven by the benefit of cost reduction initiatives and facility optimization.
Active Pharmaceutical Ingredients (API)
Three Months Ended Year Ended
December 31, December 31,
------------ ------------
(Unaudited; $ in thousands) 2014 2013 2014 2013
---- ---- ---- ----
API Contract Revenue $46,204 $38,301 $144,349 $125,871
Cost of Contract Revenue 34,200 27,975 111,873 95,144
------ ------ ------- ------
Contract Gross Profit 12,004 10,326 32,476 30,727
Contract Gross Margin 26% 27% 22% 24%
Adjusted Contract Gross Profit (1) 12,220 10,326 32,882 30,727
Adjusted Contract Gross Margin (1) 26% 27% 23% 24%
(1) Refer to Table 1 included in this release for the reconciliation of U.S. GAAP contract gross profit and contract gross margin to adjusted contract gross profit and adjusted contract gross margin as a percentage of contract revenue.
API contract revenue for the fourth quarter of 2014 increased 21% compared to the same period of 2013 due primarily an increase in API shipments to customers, and the addition of Cedarburg Pharmaceuticals. Excluding the Cedarburg acquisition, contract revenue increased 14% compared to the fourth quarter 2013. API adjusted contract margins for the fourth quarter of 2014 decreased to 26% from 27% in the fourth quarter of 2013, due to the mix of business within the segment.
For the full year 2014, API contract revenue increased 15% to $144.3 million from $125.9 million in 2013, due primarily to the addition of Cedarburg Pharmaceuticals. Excluding the acquisition of Cedarburg, API contract revenue increased 7% compared to the full year 2013. API adjusted gross margins decreased to 23% in 2014 from 24% in 2013, due to the mix of business within the segment.
Drug Product Manufacturing (DPM)
Three Months Ended Year Ended
December 31, December 31,
------------ ------------
(Unaudited; $ in thousands) 2014 2013 2014 2013
---- ---- ---- ----
DPM Contract Revenue $14,767 $3,010 $29,619 $6,712
Cost of Contract Revenue 16,449 3,100 34,919 10,175
------ ----- ------ ------
Contract Gross Loss (1,682) (90) (5,300) (3,463)
Contract Gross Margin -11% -3% -18% -52%
Adjusted Contract Gross Profit (Loss) (1) 1,761 (90) 1,467 (3,463)
Adjusted Contract Gross Margin (1) 12% -3% 5% -52%
(1) Refer to Table 1 included in this release for the reconciliation of U.S. GAAP contract gross loss and contract gross margin to adjusted contract gross profit (loss) and adjusted contract gross margin as a percentage of contract revenue.
Drug Product Manufacturing contract revenue for the fourth quarter of 2014 increased $11.8 million over the same period of 2013 and includes $10.3 million of revenue from Oso Biopharmaceuticals Manufacturing (OsoBio) that was acquired in July 2014. Drug Product adjusted contract margins for the fourth quarter of 2014 increased to 12% compared to -3% the same period of 2013, driven by volume increases, improved mix and the addition of the OsoBio business, however contract margins were significantly impacted at the Company's Albuquerque facility as a result of the previously disclosed business interruption event.
For the full year 2014, Drug Product contract revenue increased $22.9 million to $29.6 million from $6.7 million in 2013, due primarily to the addition of $16.7 million in revenue from OsoBio and a 92% increase in revenue from the company's Burlington operations. Drug Product adjusted gross margins improved to 5% in 2014 from -52% in 2013, due to the addition of OsoBio and increased capacity utilization at our Burlington facility.
Liquidity and Capital Resources
In the fourth quarter 2014, AMRI expanded its existing revolving line of credit from $50 million to $75 million with the addition of another bank to the facility.
At December 31, 2014, AMRI had cash, cash equivalents and restricted cash of $51.0 million, compared to $23.9 million at September 30, 2014. The increase in cash and cash equivalents for the quarter ended December 31, 2014 was primarily due to $35 million in proceeds from the Company's line of credit, partially offset by cash used in operations of $2.0 million and $5.2 million of capital expenditures. Total common shares outstanding, net of treasury shares, were 32,627,940 at December 31, 2014.
In January 2015, AMRI acquired a Glasgow, UK-based drug product formulation business for $24 million and expects to complete the previously announced acquisition of SSCI/ West Lafayette, Ind. in February 2015.
Financial Outlook
AMRI estimates the following for full year 2015:
-- Full year contract revenue is expected to be between $335 and $370
million, an increase of 40% at the midpoint, including
-- DDS revenue of approximately $98 million
-- API revenue of approximately $162 million
-- Drug Product revenue of approximately $92 million
-- Royalty revenue of between $13 and $14 million, including approximately
$4 million of Allegra royalties, which expire fully in the third quarter
2015
-- Adjusted selling, general and administrative expenses at approximately
17% of contract revenue
-- Adjusted EBITDA between $59 and $65 million, up 34% at the midpoint
-- Adjusted diluted EPS is expected to be between $0.80 and $0.90, compared
to $0.63 in 2014, based on an average fully diluted share count of
approximately 33 million shares
-- Capital expenditures of between $24 and $26 million
-- Effective tax rate of approximately 33%
AMRI's estimates for 2015 reflect the acquisition of the SSCI West Lafayette, Ind. operations, closing in February 2015, to be included in the DDS segment, as well as the Glasgow UK injectable drug product formulation operations, closed in January 2015, to be included in the Drug Product segment.
Fourth Quarter Results Conference Call
AMRI will host a conference call and webcast today at 8:30 a.m. ET to discuss fourth quarter 2014 results. The conference call can be accessed by dialing (866) 208-5728 (domestic calls) or (224) 633-1279 (international calls) at 8:20 a.m. ET and entering passcode 75749093. The webcast and supplementing slides can be accessed on the company's website at www.amriglobal.com.
A replay of the conference call can be accessed for 24 hours at (855) 859-2056 (domestic calls) or (404) 537-3406 (international calls) and entering passcode 75749093. Replays of the webcast can also be accessed for up to 90 days after the call via the investor area of the company's website at http://ir.amriglobal.com.
About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Solutions (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Drug Product Manufacturing supports development through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).
Forward-looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements include, but are not limited to, statements regarding the company's estimates of revenue, contract revenue, adjusted EBITDA, adjusted diluted earnings per share, and all information and other statements regarding the estimates of results and financial outlook for 2015, statements made by the company's Chief Executive Officer, and statements under the caption "Financial Outlook," statements regarding the business interruption event at the OsoBio facility and the time and resources involved with the remediation thereof and the impact of such event on the Company's results of operations, statements regarding the strength of the company's business and prospects, statements regarding the impact of recent acquisition activity, and statements concerning the company's momentum and long-term growth, including expected results for 2015. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to, trends in pharmaceutical and biotechnology companies' outsourcing of manufacturing services and chemical research and development, including softness in these markets; sales of Allegra® and the impact of the "at-risk" launch of generic Allegra®, the rapid reduction in royalties on the Allegra products expected in 2015 and the patent expirations on such products, the OTC conversion of Allegra® and the generic and OTC sales of Allegra in Japan on the company's receipt of significant royalties under the Allegra® license agreement; the success of the sales of other products for which the company receives royalties; the risk that the company will not be able to replicate either in the short or long term the revenue stream that has been derived from the royalties payable under the Allegra® license agreements; the risk that clients may terminate or reduce demand under any strategic or multi-year deal; the company's ability to enforce its intellectual property and technology rights; the company's ability to obtain financing sufficient to meet its business needs; the company's ability to successfully comply with heightened FDA scrutiny on aseptic fill/finish operations; the results of further FDA inspections; the company's ability to effectively maintain compliance with applicable FDA and DEA regulations; the company's ability to integrate past or future acquisitions, including the Aptuit West Lafayette and Glasgow operations, Cedarburg Pharmaceuticals and Oso Biopharmaceuticals Manufacturing, and make such acquisitions accretive to the company's business model, the company's ability to take advantage of proprietary technology and expand the scientific tools available to it, the ability of the company's strategic investments and acquisitions to perform as expected, as well as those risks discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission on March 17, 2014, and the company's other SEC filings. Revenue, contract revenue, adjusted diluted EPS, adjusted contract margin, adjusted EBITDA and other financial guidance offered by senior management today with respect to 2015 represent a point-in-time estimate and are based on information as of the date of this press release. Senior management has made numerous assumptions in providing this guidance which, while believed to be reasonable, may not prove to be accurate. Numerous factors, including those noted above, may cause actual results to differ materially from the guidance provided. The company expressly disclaims any current intention or obligation to update the guidance provided or any other forward-looking statement in this press release to reflect future events or changes in facts assumed for purposes of providing this guidance or otherwise affecting the forward-looking statements contained in this press release.
Non-GAAP Adjustment Items
To supplement our financial results prepared in accordance with U.S. GAAP, we have presented non-GAAP measures of contract gross profit (loss), contract gross margin, income (loss) from operations, and net income (loss) and income (loss) per diluted share as adjusted to exclude certain restructuring charges, executive transition costs, convertible debt interest and amortization charges, business interruption charges, business acquisition costs, litigation settlement charges, write-offs of deferred financing costs, non-cash long-lived asset impairment charges, losses on disposals of assets related to restructuring activities, insurance demutualization gains, depreciation and amortization of purchase accounting adjustments, non-recurring income tax adjustments, and postretirement benefit plan settlement gains in the 2014 and 2013 periods. We have also presented non-GAAP measures of adjusted EBITDA, which in addition to the items excluded above, further excluded the impact of interest income and expense, depreciation and amortization expense, and income tax expense or benefit. Exclusion of these non-recurring items allows comparisons of operating results that are consistent over time. We believe presentation of these non-GAAP measures enhances an overall understanding of our historical financial performance because we believe they are an indication of the performance of our base business. Management uses these non-GAAP measures as a basis for evaluating our financial performance as well as for budgeting and forecasting of future periods. For these reasons, we believe they can be useful to investors. The presentation of this additional information should not be considered in isolation or as a substitute for income (loss) from operations, net income (loss) or income (loss) per diluted share, prepared in accordance with U.S. GAAP. Reconciliations of these non-GAAP measures to the most directly comparable GAAP financial measures are set forth in Tables 1-3. Our projected 2015 adjusted EPS and adjusted EBITDA, however, are only provided on an adjusted basis. It is not feasible to provide GAAP EPS and EBITDA guidance because the items excluded are difficult to predict and estimate and are primarily dependent on future events.
Albany Molecular Research, Inc.
Condensed Consolidated Statements of Operations (unaudited)
Three Months Ended Year Ended
------------------ ----------
(Dollars in thousands, except for per share data) December 31, December 31, December 31, December 31,
2014 2013 2014 2013
---- ---- ---- ----
Contract revenue $80,712 $59,715 $250,705 $210,001
Recurring royalties 5,888 7,407 25,866 36,574
----- ----- ------ ------
Total revenue 86,600 67,122 276,571 246,575
------ ------ ------- -------
Cost of contract revenue 66,131 47,103 209,193 171,923
Technology incentive award 344 513 1,621 2,767
Research and development 229 44 1,004 414
Selling, general and administrative 13,954 11,004 48,898 42,256
Postretirement benefit plan settlement gain - (1,285)
Restructuring charges 146 1,075 3,582 7,183
Impairment charges 2,885 417 7,835 1,857
----- --- ----- -----
Total operating expenses 83,689 60,156 270,848 226,400
------ ------ ------- -------
Income from operations 2,911 6,966 5,723 20,175
Interest expense, net (2,700) (1,000) (10,956) (1,244)
Other (expense) income, net (238) (99) (235) 772
---- --- ---- ---
(Loss) income before income taxes (27) 5,867 (5,468) 19,703
Income tax expense (benefit) 1,834 1,603 (2,190) 7,935
----- ----- ------ -----
Net (loss)income $(1,861) $4,264 $(3,278) $11,768
======= ====== ======= =======
Basic (loss) income per share $(0.06) $0.14 $(0.10) $0.38
====== ===== ====== =====
Diluted (loss) income per share $(0.06) $0.13 $(0.10) $0.37
------ ----- ------ -----
Albany Molecular Research, Inc.
Selected Consolidated Balance Sheet Data (unaudited)
(Dollars in thousands) December 31, December 31,
2014 2013
---- ----
Cash and cash equivalents........................................................ $46,995 $175,928
Restricted cash.......................................................................... 4,052 714
Accounts receivable, net........................................................... 71,644 52,216
Royalty income receivable......................................................... 5,061 7,523
Inventory.................................................................................... 49,880 31,991
Total current assets................................................................... 191,012 279,019
Restricted cash.......................................................................... - 3,810
Property and equipment, net...................................................... 165,475 127,775
Total assets............................................................................... 519,953 445,268
Total current liabilities................................................................ 48,690 48,849
Long?term debt, excluding current installments, net of unamortized 159,980 123,135
discount................................................................................
Total liabilities............................................................................. 278,131 204,511
Total stockholders' equity.......................................................... 241,822 240,757
Total liabilities and stockholders' equity..................................... 519,953 445,268
Table 1: Reconciliation of three months and year ended December 31, 2014 and 2013 reported contract gross profit (loss) and contract gross margin to adjusted contract gross profit (loss) and adjusted contract gross margin
Non-GAAP Measures Three Months Ended Year Ended
(Dollars in thousands) December 31, December 31,
------------ ------------
2014 2013 2014 2013
---- ---- ---- ----
Consolidated Contract Revenue, as reported $80,712 $59,715 $250,705 $210,001
Consolidated Cost of Contract Revenue, as reported 66,131 47,103 209,193 171,923
------ ------ ------- -------
Consolidated Contract Gross Profit, as reported 14,581 12,612 41,512 38,078
add: Business interruption charges 3,328 - 6,445 -
add: Purchase accounting depreciation 331 - 694 -
add: Business acquisition costs - - 34 -
--- --- --- ---
Consolidated Contract Gross Profit, as adjusted $18,240 $12,612 $48,685 $38,078
======= ======= ======= =======
Consolidated Contract Gross Margin, as reported 18% 21% 17% 18%
Consolidated Contract Gross Margin, as adjusted 23% 21% 19% 18%
API Segment Contract Revenue, as reported $46,204 $38,301 $144,349 $125,871
API Segment Cost of Contract Revenue, as reported 34,200 27,975 111,873 95,144
------ ------ ------- ------
API Segment Contract Gross Profit, as reported 12,004 10,326 32,476 30,727
add: Purchase accounting depreciation 216 - 406 -
--- --- --- ---
API Segment Contract Gross Profit, as adjusted $12,220 $10,326 $32,882 $30,727
======= ======= ======= =======
API Segment Contract Gross Margin, as reported 26% 27% 22% 24%
API Segment Contract Gross Margin, as adjusted 26% 27% 23% 24%
Drug Product Segment Contract Revenue, as reported $14,767 $3,010 $29,619 $6,712
Drug Product Segment Cost of Contract Revenue, as reported 16,449 3,100 34,919 10,175
------ ----- ------ ------
Drug Product Segment Contract Gross Loss, as reported (1,682) (90) (5,300) (3,463)
add: Business interruption charges 3,328 - 6,445 -
add: Purchase accounting depreciation 115 - 288 -
add: Business acquisition costs - - 34 -
--- --- --- ---
Drug Product Segment Contract Gross Profit (Loss), as adjusted $1,761 $(90) $1,467 $(3,463)
====== ==== ====== =======
Drug Product Segment Contract Margin, as reported -11% -3% -18% -52%
Drug Product Segment Contract Margin, as adjusted 12% -3% 5% -52%
Table 2: Reconciliation of three months and year ended December 31, 2014 and 2013 reported income from operations, net income (loss) and earnings (loss) per diluted share to adjusted income from operations, adjusted net income and adjusted earnings per share:
(Dollars in thousands, except for per share data)
Non-GAAP Measures
QTD QTD YTD YTD
December 31, December 31, December 31, December 31,
2014 2013 2014 2013
---- ---- ---- ----
Income from operations, as reported $2,911 $6,966 $5,723 $20,175
Impairment charges 2,885 417 7,835 1,857
Restructuring charges 146 1,075 3,582 7,183
Business interruption charges 3,511 - 6,628 -
Executive transition costs - 1,115 626 1,630
Business acquisition costs 1,083 - 3,721 -
Purchase accounting depreciation and amortization 913 - 1,941 -
Postretirement benefit plan settlement gain - - (1,285) -
Litigation costs 25 - 25 1,946
ERP implementation costs 144 - 144 -
Organization costs 140 - 140 -
Income from operations, as adjusted $11,758 $9,573 $29,080 $32,791
======= ====== ======= =======
Net (loss), income as reported $(1,861) $4,264 $(3,278) $11,768
Adjustments, net of tax:
Impairment charges 2,030 223 5,676 1,476
Restructuring charges 106 962 2,870 5,362
Business interruption charges 2,282 - 4,308 -
Executive transition costs - 725 407 1,060
Business acquisition costs 704 - 2,418 -
Purchase accounting depreciation and amortization 593 - 1,262 -
Postretirement benefit plan settlement gain - - (835) -
Convertible debt interest and amortization charges 1,669 609 6,577 609
Write-off of deferred financing costs - - 286 -
Litigation settlement 16 - 16 1,265
Insurance demutualization gain - - - (252)
Loss on disposal of assets - - - 63
ERP implementation costs 94 - 94 -
Organization costs 91 - 91 -
Cumulative translation adjustment loss - Hungary 734 - 734 -
Non-recurring income tax adjustments 2,739 46 24 184
Net income, as adjusted $9,197 $6,829 $20,650 $21,535
------ ------ ------- -------
(Loss) income per diluted share, as reported $(0.06) $0.13 $(0.10) $0.37
Adjustments, net of tax:
Impairment charges 0.06 0.01 0.17 0.05
Restructuring charges 0.01 0.03 0.09 0.17
Business interruption charges 0.07 - 0.13 -
Executive transition costs - 0.02 0.01 0.03
Business acquisition costs 0.02 - 0.08 -
Purchase accounting depreciation and amortization 0.02 - 0.04 -
Postretirement benefit plan settlement gain - - (0.02) -
Convertible debt interest and amortization charges 0.05 0.02 0.20 0.02
Write-off of deferred financing costs - - 0.01 -
Loss on disposal of assets - - - -
Litigation settlement - - - 0.04
Insurance demutualization gain - - - (0.01)
ERP implementation costs - - - -
Organization costs - - - -
Cumulative translation adjustment loss - Hungary 0.02 - 0.02 -
Non-recurring income tax adjustments 0.09 - - 0.01
---- --- --- ----
Income per diluted share, as adjusted $0.28 $0.21 $0.63 $0.68
===== ===== ===== =====
Table 3: Reconciliation of three months and year ended December 31, 2014 and 2013 reported income (loss) from operations to adjusted EBITDA:
QTD QTD YTD YTD
December 31, December 31, December 31, December 31,
2014 2013 2014 2013
---- ---- ---- ----
Income from operations, as reported $2,911 $6,966 $5,723 $20,175
Impairment charges 2,885 417 7,835 1,857
Restructuring charges 146 1,075 3,582 7,183
Business interruption charges 3,511 - 6,628 -
Executive transition costs - 1,115 626 1,630
Business acquisition costs 1,083 - 3,721 -
Postretirement benefit plan settlement gain - - (1,285) -
Litigation costs 25 - 25 1,946
ERP implementation costs 144 - 144 -
Organization costs 140 - 140 -
--- --- --- ---
Income from operations, as adjusted $10,845 $9,573 $27,139 $32,791
Add: Non-operating (expense) income net, as reported (238) (99) (235) 772
Deduct: Insurance demutualization gain - - - (388)
Add: Cumulative translation adjustment loss - Hungary 734 - 734 -
Add: Loss on disposal of assets - - - 97
Add: Depreciation and amortization 5,287 3,920 18,353 15,871
----- ----- ------ ------
Adjusted EBITDA $16,628 $13,394 $45,991 $49,143
======= ======= ======= =======
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/amri-announces-fourth-quarter-and-full-year-2014-results-300035129.html
SOURCE AMRI
